AP Biosciences

AP Biosciences PEG

The PEG Ratio (Price/Earnings-to-Growth) of AP Biosciences (6945.TWO) as of Nov 17, 2026 is 26,950.44.

PEG

26,950.44

Last updated:

PEG Ratio (Price/Earnings-to-Growth) of AP Biosciences is 2020 26,950.44 . PEG Ratio (Price/Earnings-to-Growth) of AP Biosciences was 2019 - . It decreases by % lower compared to the previous year.

The AP Biosciences PEG history

The AP Biosciences PEG history
YEARPEGYoY
26,950.44—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

AP Biosciences Stock analysis

What does AP Biosciences do? AP Biosciences Inc generates revenue through the development and commercialization of protein and antibody drugs. The company focuses on early-stage drug candidates and preclinical trials, utilizing its technology platforms to create monoclonal and bispecific antibody drugs. Key products include IBI302, OmniMab, AP505, T-cube, and AP203, which target specific disease mechanisms and therapeutic areas. The primary buyers are pharmaceutical companies seeking to expand their drug pipelines through partnerships and licensing agreements. The firm's technology platforms, such as OmniMab fully human antibody library and T-cube, enable the development of novel bispecific antibodies. These platforms support the creation of drugs like AP505-PD-L1 x VEGF bispecific antibody and AP203-PD-L1 x CD137 fully human bispecific antibody, which are designed for specific therapeutic targets. The company's research and development efforts target diseases with high unmet medical needs, attracting interest from potential collaborators in the biopharmaceutical sector. AP Biosciences Inc's business model relies on advancing its pipeline of drug candidates through preclinical and clinical stages, with the goal of securing partnerships or licensing deals with larger pharmaceutical firms. The company's focus on bispecific antibody technology and its proprietary platforms positions it to generate revenue from milestone payments and royalties upon successful development and commercialization of its drug candidates. AP Biosciences is one of the most popular companies on Eulerpool.

Frequently Asked Questions about AP Biosciences stock

PEG Ratio (Price/Earnings-to-Growth) of AP Biosciences is 26,950.44 in 2020.

On Eulerpool you can find the complete historical development of PEG Ratio (Price/Earnings-to-Growth) AP Biosciences since 2006 – with annual values, charts, and detailed analysis.

The PEG ratio adjusts the P/E ratio by the expected earnings growth rate. A PEG below 1 may indicate an undervalued stock relative to its growth potential.

PEG = P/E Ratio / Expected Annual EPS Growth Rate

To evaluate PEG Ratio (Price/Earnings-to-Growth)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for PEG Ratio (Price/Earnings-to-Growth).

A 'good' varies by industry and company stage. On Eulerpool, you can compare PEG Ratio (Price/Earnings-to-Growth)'s AP Biosciences with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — AP Biosciences

All Key Metrics — AP Biosciences